Mineralocorticoids and Cardiovascular Disease in Females with Insulin Resistance and Obesity
- 146 Downloads
Purpose of the Review
In the present review, we will discuss the evidence and the mechanisms underlying the complex interplay between obesity, mineralocorticoid receptor activation, and cardiovascular dysfunction with special emphasis on the pathogenesis of cardiovascular disease (CVD) in obese and insulin-resistant females.
Since the initial isolation of aldosterone in 1953 and the cloning of the mineralocorticoid receptor (MR) decades later, our understanding has expanded tremendously regarding their involvement in the pathogenesis of CVD. Recent results from both pre-clinical and clinical studies support a close correlation between increase adiposity and enhanced aldosterone production (MR activation).
Importantly, insulin resistance and obese females are more prone to the deleterious cardiovascular effects of MR activation, and enhanced MR activation in females has emerged as an important causative event in the genesis of a more severe CVD in diabetic women. Different clinical trials have been completed examining the effect of MR blockade in subjects with CVD. Despite its important beneficial mortality impact, side effects are frequent and a newer MR antagonist, finerenone, with less risk of hyperkalemia is currently being tested in large clinical trials.
KeywordsObesity Females Cardiovascular disease Aldosterone Mineralocorticoid receptor
Compliance with Ethics Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 3.Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132(10):923–31.CrossRefPubMedGoogle Scholar
- 4.George J, Rapsomaniki E, Pujades-Rodriguez M, Shah AD, Denaxas S, Herrett E, et al. How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1,937,360 people. Circulation. 2015;132(14):1320–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Gregg, E.W. et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol 2014.Google Scholar
- 46.Fuster D, Frey FJ, Ferrari P. Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure. Praxis (Bern 1994). 2000;89(49):2073–6.Google Scholar
- 49.Hugues FC, Gourlot C, Le Jeunne C. Drug-induced gynecomastia. Ann Med Interne (Paris). 2000;151(1):10–7.Google Scholar
- 52.Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.CrossRefPubMedGoogle Scholar
- 53.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Cooper LB, et al. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc. 2017;6(12)Google Scholar
- 58.• Grune J, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenon’s antifibrotic activity. Hypertension. 2018;71(4):599–608. This investigation examines the antifibrotic role of finerenone in a rodent model of heart failure via inhibition of TNX expression. CrossRefPubMedGoogle Scholar
- 60.Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–14.CrossRefPubMedPubMedCentralGoogle Scholar
- 69.•• Huby A-C, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132(22):2134–45. This investigation elegantly dsecribes how leptin regulates aldosterone synthesis and how leptin-mediated increased aldosterone secretion results in endothelial dysfunction and cardiac fibrosis. CrossRefPubMedGoogle Scholar
- 70.• Huby AC, Otvos L Jr, Belin de Chantemele EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension. 2016;67(5):1020–8. The investigation shows that that leptin results in hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. CrossRefPubMedPubMedCentralGoogle Scholar
- 75.•• Davel AP, et al. Sex-specific mechanisms of resistance vessel endothelial dysfunction induced by cardiometabolic risk factors. J Am Heart Assoc. 2018;7(4):e007675. This paper examines the differential role of endothelial cell mineralocortidoid receptor activation in the genesis of endothelial dysfunction in obese and hyperlipidemic female mice when compared with males. CrossRefPubMedPubMedCentralGoogle Scholar